Main Therapeutic Uses

Corvasal, containing the active ingredient molsidomine, is primarily used for the long-term treatment and prevention of stable and unstable angina pectoris. It belongs to a class of medications known as vasodilators, which work by relaxing and widening the blood vessels.

Chronic Stable Angina

In patients with chronic stable angina, the medication is used to reduce the frequency and severity of chest pain episodes. By dilating the venous blood vessels, it reduces the amount of blood returning to the heart, thereby lowering the workload and oxygen demand of the cardiac muscle.

Unstable Angina

For individuals experiencing unstable angina, Corvasal can be utilized as part of a broader therapeutic approach to improve blood flow and oxygen delivery to the heart, helping to stabilize the condition and prevent further ischemic events.

Post-Infarction Care

In certain clinical scenarios following a myocardial infarction (heart attack), the medication may be prescribed once the patient is hemodynamically stable to manage persistent ischemic symptoms and improve cardiac function efficiency.

Benefits and Mechanism of Action

Improved Exercise Tolerance

By optimizing the balance between myocardial oxygen supply and demand, Corvasal helps patients increase their capacity for physical activity. This allows individuals to engage in daily tasks with a reduced risk of experiencing chest pain or shortness of breath.

Reduction of Preload

The primary benefit of its mechanism is the reduction of "preload." The medication releases nitric oxide, which leads to the relaxation of smooth muscles in the veins. This pooling of blood in the peripheral circulation reduces the volume of blood the heart must pump, protecting the heart muscle from overexertion.

Prevention of Vasospasms

Corvasal also aids in the dilation of large coronary arteries. This effect is particularly beneficial in preventing coronary artery spasms, ensuring a more consistent and reliable flow of oxygenated blood to the heart tissues.

Who Can and Cannot Use Corvasal?

Official regulatory documents define the eligibility for Corvasal (Molsidomine) based on absolute prohibitions and restrictions tied to the patient's condition. Use is established for adults aged 18 years and older.

---

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated if a patient has a known hypersensitivity to the active substance or is experiencing severe hypotension (very low blood pressure) or acute circulatory insufficiency, such as cardiogenic shock. Corvasal is also contraindicated for any patient concurrently taking Phosphodiesterase-5 (PDE5) inhibitors (like sildenafil) due to the risk of a severe drop in blood pressure. Use is prohibited during lactation (breastfeeding).

Key Restrictions and Limitations

The drug’s eligibility is restricted in several populations. Use is not well-established in the pediatric population (under 18 years). Patients with significant hepatic insufficiency (severe liver impairment) or major renal insufficiency (kidney impairment) require careful assessment. Use during pregnancy is restricted, considered only when the potential benefit is deemed to justify the risk. Additional caution is required for patients with severe heart valve conditions, such as severe aortic stenosis.

The official regulatory profile for Corvasal (Molsidomine) details specific constraints primarily focused on pharmacodynamic interactions that lead to potentiated blood pressure-lowering effects.

Interaction scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions:	Phosphodiesterase-5 (PDE5) Inhibitors, Antihypertensive Drugs, Vasodilators (including organic nitrates), Alcohol.
Specific interacting medicines (if explicitly listed):	Sildenafil, Tadalafil, Vardenafil (as examples of PDE5 Inhibitors).
Mechanistic basis of interactions (only if stated in label):	Primarily Pharmacodynamic—an additive hypotensive effect due to shared vasodilatory properties.
Population-specific interaction notes (if applicable):	Hepatic Impairment: Documented impaired clearance and prolonged half-life ( t1/2) of the active metabolite, resulting in increased systemic exposure. Elderly Subjects: Observed reduction in first-pass metabolism and prolonged half-life, leading to increased exposure.
Interaction-related restrictions:	Formal Contraindication against co-administration with Phosphodiesterase-5 (PDE5) Inhibitors.

Official interaction statements

• Co-administration with Phosphodiesterase-5 (PDE5) Inhibitors is strictly contraindicated due to the critical risk of a profound and sudden drop in blood pressure (severe hypotension).
• The combination with Antihypertensive Drugs or other Vasodilators is documented to have an additive hypotensive effect.
• Consumption of alcohol is officially stated to enhance the hypotensive effects of Molsidomine, potentially increasing the risk of associated symptoms.

Connection to the overall interaction profile

Regulatory documentation structures the interaction profile around the pharmacodynamic risk of combining the medicine with other hypotensive agents, establishing a formal contraindication for certain drug classes. Additionally, the profile includes label-based information on altered drug clearance and increased exposure in populations with impaired liver function and in elderly subjects.

Prodrug Activation and Nitric Oxide Release

Corvasal acts as a prodrug that undergoes metabolism to form its active metabolite, linsidomine (SIN-1). This active compound spontaneously releases Nitric Oxide (NO), a key gaseous signaling molecule. This mechanism provides a source of NO through a continuous, non-enzymatic process, which influences core mechanistic pathways of vascular regulation.

---

Targeting the cGMP Pathway and Hemodynamic Load

The released NO diffuses into vascular smooth muscle cells where it binds to and activates soluble Guanylate Cyclase (sGC). This initiates an intracellular signaling sequence that increases levels of cyclic Guanosine Monophosphate (cGMP). Elevated cGMP acts within domains involving enzyme-mediated responses to promote smooth muscle relaxation. This relaxation leads to systemic vasodilation, a resulting physiological consequence. This action modulates pathways involved in the regulation of vascular tone by decreasing venous return (preload) and reducing the resistance the heart pumps against (afterload), which results in decreased myocardial wall tension.

Corvasal (molsidomine) is an antianginal medication that must be used strictly as prescribed by a healthcare professional. It is available as oral tablets in different strengths, such as 2 mg and 4 mg.

General Administration Guidelines

• Dosage: The dose is highly individualized based on the condition being treated and the patient's response. Typical initial adult dosages for angina pectoris may range from 1 mg to 2 mg, taken two to three times daily. The dosage may be gradually increased, but generally should not exceed 12 mg to 16 mg per day, split into multiple doses.
• Frequency: The total daily dosage is usually divided and taken in two to four administrations throughout the day. This schedule is often adjusted to align with the patient’s activity and the timing of angina symptoms.
• With Meals: The tablets are generally taken orally with water, either before or after meals.
• Swallowing: Swallow the tablets whole. If the tablet is scored (such as the 2 mg tablet), it can be broken along the score line to achieve a half-dose if instructed by the prescriber.

Important Precautions

Do not suddenly stop taking Corvasal, as abrupt cessation may lead to a rebound increase in the frequency and severity of angina. If a dose is missed, take it as soon as remembered, unless it is nearly time for the next scheduled dose; in that case, skip the missed dose. Follow the dosing and administration instructions provided by your prescriber, especially concerning dose adjustments for patients with impaired liver function or those with pre-existing low blood pressure.

Research Evidence / Overview of Studies for Corvasal (Molsidomine)

---

Evidence for Use in Chronic Stable Angina Pectoris

The main body of research evaluated Corvasal in the context of chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. Studies exploring this evaluation have been primarily designed as Randomized Controlled Trials (RCTs), including double-blind, placebo-controlled, and multicenter designs, as well as comparative studies against other vasodilators.

Research examined outcomes related to physical discomfort and functional imbalance. For example, studies monitored changes in patients' ability to perform physical activity, measured through exercise tolerance tests. Research also examined outcomes reflecting daily functioning axes, which included monitoring the number of anginal episodes patients reported and the frequency of quick-relief nitrate tablet use. Additionally, some trials monitored physiological strain by measuring signs of myocardial ischemia, or lack of oxygen to the heart muscle, during exertion.

Studies describe findings related to measurements recorded in the study populations, where research monitored symptom patterns throughout the observed period. Research has also explored Molsidomine in patients who have undergone angioplasty (PCI), where studies examined changes in the health of blood vessel linings, known as endothelial function.

---

Evidence from Studies in Chronic Congestive Heart Failure

Research has studied Corvasal in the context of chronic congestive heart failure, where evidence has been developed through earlier-stage clinical trials. The research examined outcomes related to systemic or functional imbalance within the heart. Specifically, studies monitored temporary physiological imbalance by measuring acute changes in internal heart and lung pressures, such as the filling pressure in the left ventricle and pulmonary artery pressures. These findings describe patterns observed in small, specific groups of patients over very short time intervals following administration.

---

Long-Term Studies and Maintenance Evidence

Research has observed patient patterns over defined time intervals ranging up to continuous follow-up of six months to one year. However, long-term outcomes regarding major cardiovascular events are not fully established by the core randomized trials. While research provides insight into short-term changes and functional measures, evidence is limited regarding patterns measured for certain long-term vascular endpoints across all studies, and findings were mixed in some trials that examined these surrogate markers over extended periods. The long-term consistency of observed patterns is not fully known.

---

Research in Specific Patient Groups

The research base was primarily developed using the adult population with stable angina. Research describes patterns related to what was observed in populations presenting with co-existing conditions, such as patients who also have hypertension (high blood pressure) or a history of prior heart attack, and the findings apply only to the populations studied. Data for certain groups remain insufficient. For instance, there is limited information derived from dedicated randomized controlled trials regarding Molsidomine when evaluated in pediatric populations or in pregnant individuals.

---

What the Research Does Not Yet Fully Clarify

While research contributes to the broader evidence landscape for Corvasal, there are several areas where certainty remains low. The available evidence provides context, but research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Key research limitation frames include the finding that results for long-term vascular outcomes, even when measured in well-designed studies, were mixed. Comparative evidence against some newer therapies is also currently lacking. Findings describe group patterns, not personal predictions, and research highlights what is known—and what is still uncertain.

Key Studies & References

1. Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (NCT01363661)
2. [Hemodynamic effects of molsidomine in chronic congestive heart failure]

Common questions about Corvasal (FAQ)

Q: Is Corvasal the same as Molsidomine?

Yes, Corvasal is a common brand name for this medication. The medicine contains the active ingredient Molsidomine. Official product information refers to the drug by its active substance.

Q: What is linsidomine and how is it related to Corvasal's effect?

Molsidomine is known as a 'prodrug,' meaning it is inactive until the body processes it. During this process, Molsidomine is converted into its active form, which is called linsidomine (or SIN-1). Linsidomine is the substance that releases Nitric Oxide (NO) and produces the blood vessel-widening effect.

Q: Can Corvasal affect my heart rate?

Yes, regulatory documents list changes in heart rate as a common side effect. Specifically, Molsidomine is commonly associated with an increase in heart rate (Tachycardia) and palpitations. This change is considered common and is often related to the medicine's vasodilating action.

Q: Does Corvasal interact with common pain relievers like NSAIDs?

Official regulatory warnings focus on the strict contraindication with PDE5 inhibitors (like sildenafil) because these combinations carry a significant risk of a profound and sudden drop in blood pressure (severe hypotension). Separately, interactions are listed with antihypertensive drugs and other vasodilators. There is no explicit regulatory statement found in the official documents regarding interactions with common pain relievers classified as NSAIDs.

Q: Can Corvasal be used by people with kidney or liver problems?

Official information states that Molsidomine should be used with caution in patients who have impaired kidney function or significant impaired liver function. Because the drug’s processing can be affected by the liver, official information indicates that caution and a careful assessment of the dose may be required for these patients.

Q: Are there any specific warnings for women who are pregnant or breastfeeding?

Regulatory documents state that the medicine is contraindicated, meaning it must not be used, by women who are breastfeeding (lactating). Use during pregnancy is generally restricted and is only considered if a physician determines the potential benefit outweighs the possible risks.

Q: Is Corvasal available in different strengths, like 2mg and 4mg?

Yes, Corvasal is available as oral tablets. Regulatory documentation and patient information leaflets confirm that it is commonly supplied in different strengths, such as 2 mg and 4 mg.

Q: Is there a maximum daily dosage that should not be exceeded?

While the dosage is highly individualized, official information specifies that the total daily dosage generally should not exceed 12 mg to 16 mg. The total amount is typically administered in divided doses.

Q: Is Corvasal used for prevention or treating an acute angina attack?

Corvasal is indicated for the long-term treatment and prevention of chronic stable angina pectoris. Official product information notes that due to its pharmacokinetic profile, it is not suitable for treating an acute or sudden angina attack.

Q: What conditions besides angina is Corvasal used to manage?

While the primary indication is chronic stable angina, Molsidomine may also be used in association with left heart failure and in patients following an acute myocardial infarction (heart attack).

Q: How long do the effects of one Corvasal tablet last?

The active substance is eliminated from the body within a few hours. However, the beneficial effects of vasodilation may persist longer. The anti-anginal effect is designed to provide sustained coverage, and the dosage schedule is designed to account for this duration.

Q: Are there any rare but serious side effects associated with Corvasal?

Most reported side effects are common and related to blood vessel widening, but regulatory documents do list some serious effects as rare. These can include thrombocytopenia (a low platelet count) and signs of an allergic reaction, such as angioedema (swelling).

Q: Can Corvasal affect platelet function or blood clotting?

Official labeling mentions thrombocytopenia (low platelet count) as a rare side effect. Furthermore, the drug’s mechanism involves Nitric Oxide, a substance known to affect blood function.

Q: Does Corvasal come in an extended-release form?

Yes, Molsidomine is available in both an immediate-release tablet and an extended-release (or sustained-release) formulation. The specific form prescribed is based on the patient's individual treatment plan.

Q: What are the storage requirements for Corvasal tablets?

Official patient information indicates that the tablets should be stored in a cool, dry place and should not be kept at a temperature exceeding 30°C (86°F). It is important to protect the tablets from moisture and keep them out of the reach of children.

Q: Why is Corvasal sometimes prescribed for chronic heart failure?

Corvasal is indicated for use in association with left heart failure. It causes vasodilation (widening of blood vessels), which reduces the pressure and volume of blood returning to the heart (preload) and the resistance the heart must pump against (afterload), thereby reducing the workload on the heart.

Q: How quickly is Corvasal absorbed into the body after taking a tablet?

Official pharmacokinetic studies show that Molsidomine is rapidly absorbed after being swallowed. It reaches its peak concentration in the blood within approximately one to two hours after administration.

Q: What is the typical half-life of Corvasal's active component in the blood?

The half-life is the time it takes for half of the active substance to be eliminated from the body. For the active metabolite, linsidomine (SIN-1), this half-life is approximately 1 to 2 hours.

Q: Are there any known hypersensitivity or allergic reactions to Corvasal?

Yes, regulatory labeling states that the medicine is strictly contraindicated if a patient has a known hypersensitivity or allergy to the active substance, Molsidomine. Signs of an allergic reaction, such as Angioedema (swelling), have also been reported as a rare side effect.

Q: Is Corvasal taken with or without food?

According to the official administration guidelines, the tablets should be swallowed whole with water. They are generally taken either before or after meals.

Corvasal (molsidomine) must be stored and disposed of in strict accordance with official regulatory labeling to preserve product integrity and ensure public safety.

Storage Requirements

Requirement Category	Official Regulatory Statement
Storage Temperature	Store at a temperature not exceeding 30 C (86 F).
Environmental Protection	Protect from moisture and store in a cool, dry place.
Handling Constraints	Do not freeze. Keep the container tightly closed.
Child Safety	Keep medicine out of reach of children.

Disposal Instructions

Official disposal requires utilizing a drug take-back program whenever available. If no take-back option is accessible, unused or expired product should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container before being thrown in the household trash. The labeling advises not flushing the medicine down the toilet or pouring it down a sink.